MIST רווח למניה בשנים עשר החודשים האחרונים Milestone Pharma

The 12-month net income per share trend for Milestone Pharmaceuticals (MIST) highlights the impact of mucosal delivery patents and Phase 3 trial costs. The value of -0.69 reflects the current metric level amid FDA approval risks for the nasal spray and reliance on external capital. Business stability is supported by the expanded application of the lead molecule and global licensing agreements.

Milestone Pharmaceuticals (MIST) is strengthening its position in emergency cardiology by integrating rhythm-control medications into clinical practice. By analyzing the company's rolling annual earnings per share, an investor can view the net income over 12 months divided by the number of shares, which allows for an assessment of real business efficiency without dilution distortions and helps determine the asset's fair value.